Q1 FY2027 · ended Jun 30, 2026 · Revenue $32.36M, -19.5% YoY · Filed Aug 13, 2026
Elite Pharmaceuticals, Inc. (ELTP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q1 of fiscal 2027, the quarter ended Jun 30, 2026, it reported revenue of $32.4 million and net income of $5.9 million. Free cash flow was $9.3 million. As of Jun 30, 2026 it held $38.9 million in cash and investments and $2.6 million in total debt.
Revenue
$32.36M
-19.5% vs year-ago quarter
Net income
$5.91M
+200.4% vs year-ago quarter
Operating cash flow
$10.07M
-31.8% vs year-ago quarter
Free cash flow
$9.26M
-36.4% vs year-ago quarter
EPS
$0.01
+200.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
1.08B
+0.6% vs year-ago quarter
Net cash
$36.38M
Q1 FY2027
Operating margin
24.8%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELTP (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- NJ
- Headquarters
- Northvale, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1053369
- Former names
- ELITE PHARMACEUTICALS INC /DE/ (until Feb 8, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Jun 30, 2026 |
Q4 FY2026 Mar 31, 2026 |
Q3 FY2026 Dec 31, 2025 |
Q2 FY2026 Sep 30, 2025 |
Q1 FY2026 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $32.4M | $40.7M | $31.6M | $36.3M | $40.2M |
| Operating income | $7.5M | $10.2M | $9.0M | $8.2M | $21.7M |
| Net income | $5.9M | $18.5M | $18.6M | $13.7M | -$5.9M |
| Diluted EPS | $0.01 | $0.02 | $0.01 | $0.01 | -$0.01 |
| Operating cash flow | $10.1M | $9.1M | -$5.3M | $5.1M | $14.8M |
| Free cash flow | $9.3M | $8.7M | -$5.5M | $5.0M | $14.6M |
| Total assets | $139.7M | $138.3M | $126.4M | $117.2M | $111.3M |
| Total liabilities | $34.8M | $39.4M | $46.1M | $55.7M | $63.7M |
| Stockholders' equity | $104.8M | $98.9M | $80.3M | $61.6M | $47.7M |
| Cash and investments | $38.9M | $29.8M | $21.1M | $26.6M | $21.7M |
| Total debt | $2.6M | $2.8M | $3.0M | $3.2M | $3.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 3, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K/A |
Amended current report
Regulation FD disclosure
|
Aug 11, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 4, 2026 | Aug 4, 2026 |
All 1000 Elite Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.